Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Lo-Zumandimine

&times

Overview

What is Lo-Zumandimine?

Lo-Zumandimine (drospirenone and ethinyl estradiol tablets, USP) provides an oral contraceptive regimen consisting of 24 light pink to pink active uncoated tablets each containing 3 mg of drospirenone USP and 0.02 mg of ethinyl estradiol USP and 4 green inert uncoated tablets. The inactive ingredients in the light pink to pink tablets are corn starch, FD&C Red No. 40, lactose monohydrate, magnesium stearate, povidone, talc and vitamin-E. The green inert uncoated tablets contain anhydrous lactose, croscarmellose sodium, FD &C Blue No. 2 aluminum lake, ferric oxide yellow, magnesium stearate, microcrystalline cellulose and povidone. Drospirenone (6R,7R,8R,9S,10R,13S,14S,15S,16S,17S)-1,3’,4’,6,6a,7,8,9,10,11,12,13,14,15, 15a,16-hexadecahydro­-10,13-dimethylspiro-[17H-dicyclopropa-[6,7:15,16]cyclopenta[a] phenanthrene-17,2’(5H)-furan]-3,5’(2H)-dione) is a synthetic progestational compound and has a molecular weight of 366.5 and a molecular formula of CHO. Ethinyl estradiol (19-nor-17α-pregna 1,3,5(10)-triene-20-yne-3, 17-diol) is a synthetic estrogenic compound and has a molecular weight of 296.4 and a molecular formula of CHO. The structural formulas are as follows:

USP Dissolution Test is pending. 



What does Lo-Zumandimine look like?



What are the available doses of Lo-Zumandimine?

Lo-Zumandimine consists of    28 uncoated, flat faced, beveled-edge tablets in the following order :

What should I talk to my health care provider before I take Lo-Zumandimine?

Nursing Mothers: Not recommended; can decrease milk production.

How should I use Lo-Zumandimine?

Lo-Zumandimine™ is indicated  for use by women to prevent pregnancy.

Take one tablet by mouth at the same time every day. The failure rate may increase when pills are missed or taken incorrectly. To achieve maximum contraceptive and PMDD effectiveness, Lo-Zumandimine must be taken exactly as directed, in the order directed on the blister pack. Single missed pills should be taken as soon as remembered.


What interacts with Lo-Zumandimine?

Sorry No Records found


What are the warnings of Lo-Zumandimine?

Sorry No Records found


What are the precautions of Lo-Zumandimine?

Sorry No Records found


What are the side effects of Lo-Zumandimine?

Sorry No records found


What should I look out for while using Lo-Zumandimine?

Do not prescribe Lo-Zumandimine to women who are known to have the following:

Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke .


What might happen if I take too much Lo-Zumandimine?

There have been no reports of serious ill effects from overdose, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea. DRSP is a spironolactone analogue which has anti-mineralocorticoid properties. Serum concentration of potassium and sodium, and evidence of metabolic acidosis, should be monitored in cases of overdose.


How should I store and handle Lo-Zumandimine?

Topiramate extended-release capsules should be stored in well-closed containers at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].Protect from moisture and light.Topiramate extended-release capsules should be stored in well-closed containers at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].Protect from moisture and light.Risedronate Sodium Tablets, USP are available containing 5 mg, 30 mg, 35 mg or 150 mg risedronate sodium, USP.The 5 mg tablets are light beige, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4044-93bottles of 30 tabletsNDC 0378-4044-05bottles of 500 tabletsThe 30 mg tablets are white, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4114-93bottles of 30 tabletsNDC 0378-4114-05bottles of 500 tabletsThe 35 mg tablets are light orange, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4714-99unit of use blister card containing 4 tabletsNDC 0378-4714-92carton of 10 cards each containing 4 tabletsNDC 0378-4714-96unit of use blister card containing 12 tabletsNDC 0378-4714-78carton of 10 cards each containing 12 tabletsThe 150 mg tablets are light blue, film-coated, round, unscored tablets debossed with over on one side of the tablet and on the other side. They are available as follows:NDC 0378-4150-32unit of use blister card containing 1 tabletNDC 0378-4150-97carton of 10 cards each containing 1 tabletNDC 0378-4150-53unit of use blister card containing 3 tabletsNDC 0378-4150-93carton of 10 cards each containing 3 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Risedronate Sodium Tablets, USP are available containing 5 mg, 30 mg, 35 mg or 150 mg risedronate sodium, USP.The 5 mg tablets are light beige, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4044-93bottles of 30 tabletsNDC 0378-4044-05bottles of 500 tabletsThe 30 mg tablets are white, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4114-93bottles of 30 tabletsNDC 0378-4114-05bottles of 500 tabletsThe 35 mg tablets are light orange, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4714-99unit of use blister card containing 4 tabletsNDC 0378-4714-92carton of 10 cards each containing 4 tabletsNDC 0378-4714-96unit of use blister card containing 12 tabletsNDC 0378-4714-78carton of 10 cards each containing 12 tabletsThe 150 mg tablets are light blue, film-coated, round, unscored tablets debossed with over on one side of the tablet and on the other side. They are available as follows:NDC 0378-4150-32unit of use blister card containing 1 tabletNDC 0378-4150-97carton of 10 cards each containing 1 tabletNDC 0378-4150-53unit of use blister card containing 3 tabletsNDC 0378-4150-93carton of 10 cards each containing 3 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Risedronate Sodium Tablets, USP are available containing 5 mg, 30 mg, 35 mg or 150 mg risedronate sodium, USP.The 5 mg tablets are light beige, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4044-93bottles of 30 tabletsNDC 0378-4044-05bottles of 500 tabletsThe 30 mg tablets are white, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4114-93bottles of 30 tabletsNDC 0378-4114-05bottles of 500 tabletsThe 35 mg tablets are light orange, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4714-99unit of use blister card containing 4 tabletsNDC 0378-4714-92carton of 10 cards each containing 4 tabletsNDC 0378-4714-96unit of use blister card containing 12 tabletsNDC 0378-4714-78carton of 10 cards each containing 12 tabletsThe 150 mg tablets are light blue, film-coated, round, unscored tablets debossed with over on one side of the tablet and on the other side. They are available as follows:NDC 0378-4150-32unit of use blister card containing 1 tabletNDC 0378-4150-97carton of 10 cards each containing 1 tabletNDC 0378-4150-53unit of use blister card containing 3 tabletsNDC 0378-4150-93carton of 10 cards each containing 3 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Risedronate Sodium Tablets, USP are available containing 5 mg, 30 mg, 35 mg or 150 mg risedronate sodium, USP.The 5 mg tablets are light beige, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4044-93bottles of 30 tabletsNDC 0378-4044-05bottles of 500 tabletsThe 30 mg tablets are white, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4114-93bottles of 30 tabletsNDC 0378-4114-05bottles of 500 tabletsThe 35 mg tablets are light orange, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4714-99unit of use blister card containing 4 tabletsNDC 0378-4714-92carton of 10 cards each containing 4 tabletsNDC 0378-4714-96unit of use blister card containing 12 tabletsNDC 0378-4714-78carton of 10 cards each containing 12 tabletsThe 150 mg tablets are light blue, film-coated, round, unscored tablets debossed with over on one side of the tablet and on the other side. They are available as follows:NDC 0378-4150-32unit of use blister card containing 1 tabletNDC 0378-4150-97carton of 10 cards each containing 1 tabletNDC 0378-4150-53unit of use blister card containing 3 tabletsNDC 0378-4150-93carton of 10 cards each containing 3 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Risedronate Sodium Tablets, USP are available containing 5 mg, 30 mg, 35 mg or 150 mg risedronate sodium, USP.The 5 mg tablets are light beige, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4044-93bottles of 30 tabletsNDC 0378-4044-05bottles of 500 tabletsThe 30 mg tablets are white, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4114-93bottles of 30 tabletsNDC 0378-4114-05bottles of 500 tabletsThe 35 mg tablets are light orange, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4714-99unit of use blister card containing 4 tabletsNDC 0378-4714-92carton of 10 cards each containing 4 tabletsNDC 0378-4714-96unit of use blister card containing 12 tabletsNDC 0378-4714-78carton of 10 cards each containing 12 tabletsThe 150 mg tablets are light blue, film-coated, round, unscored tablets debossed with over on one side of the tablet and on the other side. They are available as follows:NDC 0378-4150-32unit of use blister card containing 1 tabletNDC 0378-4150-97carton of 10 cards each containing 1 tabletNDC 0378-4150-53unit of use blister card containing 3 tabletsNDC 0378-4150-93carton of 10 cards each containing 3 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Risedronate Sodium Tablets, USP are available containing 5 mg, 30 mg, 35 mg or 150 mg risedronate sodium, USP.The 5 mg tablets are light beige, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4044-93bottles of 30 tabletsNDC 0378-4044-05bottles of 500 tabletsThe 30 mg tablets are white, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4114-93bottles of 30 tabletsNDC 0378-4114-05bottles of 500 tabletsThe 35 mg tablets are light orange, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4714-99unit of use blister card containing 4 tabletsNDC 0378-4714-92carton of 10 cards each containing 4 tabletsNDC 0378-4714-96unit of use blister card containing 12 tabletsNDC 0378-4714-78carton of 10 cards each containing 12 tabletsThe 150 mg tablets are light blue, film-coated, round, unscored tablets debossed with over on one side of the tablet and on the other side. They are available as follows:NDC 0378-4150-32unit of use blister card containing 1 tabletNDC 0378-4150-97carton of 10 cards each containing 1 tabletNDC 0378-4150-53unit of use blister card containing 3 tabletsNDC 0378-4150-93carton of 10 cards each containing 3 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Risedronate Sodium Tablets, USP are available containing 5 mg, 30 mg, 35 mg or 150 mg risedronate sodium, USP.The 5 mg tablets are light beige, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4044-93bottles of 30 tabletsNDC 0378-4044-05bottles of 500 tabletsThe 30 mg tablets are white, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4114-93bottles of 30 tabletsNDC 0378-4114-05bottles of 500 tabletsThe 35 mg tablets are light orange, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4714-99unit of use blister card containing 4 tabletsNDC 0378-4714-92carton of 10 cards each containing 4 tabletsNDC 0378-4714-96unit of use blister card containing 12 tabletsNDC 0378-4714-78carton of 10 cards each containing 12 tabletsThe 150 mg tablets are light blue, film-coated, round, unscored tablets debossed with over on one side of the tablet and on the other side. They are available as follows:NDC 0378-4150-32unit of use blister card containing 1 tabletNDC 0378-4150-97carton of 10 cards each containing 1 tabletNDC 0378-4150-53unit of use blister card containing 3 tabletsNDC 0378-4150-93carton of 10 cards each containing 3 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Risedronate Sodium Tablets, USP are available containing 5 mg, 30 mg, 35 mg or 150 mg risedronate sodium, USP.The 5 mg tablets are light beige, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4044-93bottles of 30 tabletsNDC 0378-4044-05bottles of 500 tabletsThe 30 mg tablets are white, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4114-93bottles of 30 tabletsNDC 0378-4114-05bottles of 500 tabletsThe 35 mg tablets are light orange, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4714-99unit of use blister card containing 4 tabletsNDC 0378-4714-92carton of 10 cards each containing 4 tabletsNDC 0378-4714-96unit of use blister card containing 12 tabletsNDC 0378-4714-78carton of 10 cards each containing 12 tabletsThe 150 mg tablets are light blue, film-coated, round, unscored tablets debossed with over on one side of the tablet and on the other side. They are available as follows:NDC 0378-4150-32unit of use blister card containing 1 tabletNDC 0378-4150-97carton of 10 cards each containing 1 tabletNDC 0378-4150-53unit of use blister card containing 3 tabletsNDC 0378-4150-93carton of 10 cards each containing 3 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Risedronate Sodium Tablets, USP are available containing 5 mg, 30 mg, 35 mg or 150 mg risedronate sodium, USP.The 5 mg tablets are light beige, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4044-93bottles of 30 tabletsNDC 0378-4044-05bottles of 500 tabletsThe 30 mg tablets are white, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4114-93bottles of 30 tabletsNDC 0378-4114-05bottles of 500 tabletsThe 35 mg tablets are light orange, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4714-99unit of use blister card containing 4 tabletsNDC 0378-4714-92carton of 10 cards each containing 4 tabletsNDC 0378-4714-96unit of use blister card containing 12 tabletsNDC 0378-4714-78carton of 10 cards each containing 12 tabletsThe 150 mg tablets are light blue, film-coated, round, unscored tablets debossed with over on one side of the tablet and on the other side. They are available as follows:NDC 0378-4150-32unit of use blister card containing 1 tabletNDC 0378-4150-97carton of 10 cards each containing 1 tabletNDC 0378-4150-53unit of use blister card containing 3 tabletsNDC 0378-4150-93carton of 10 cards each containing 3 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Risedronate Sodium Tablets, USP are available containing 5 mg, 30 mg, 35 mg or 150 mg risedronate sodium, USP.The 5 mg tablets are light beige, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4044-93bottles of 30 tabletsNDC 0378-4044-05bottles of 500 tabletsThe 30 mg tablets are white, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4114-93bottles of 30 tabletsNDC 0378-4114-05bottles of 500 tabletsThe 35 mg tablets are light orange, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4714-99unit of use blister card containing 4 tabletsNDC 0378-4714-92carton of 10 cards each containing 4 tabletsNDC 0378-4714-96unit of use blister card containing 12 tabletsNDC 0378-4714-78carton of 10 cards each containing 12 tabletsThe 150 mg tablets are light blue, film-coated, round, unscored tablets debossed with over on one side of the tablet and on the other side. They are available as follows:NDC 0378-4150-32unit of use blister card containing 1 tabletNDC 0378-4150-97carton of 10 cards each containing 1 tabletNDC 0378-4150-53unit of use blister card containing 3 tabletsNDC 0378-4150-93carton of 10 cards each containing 3 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Risedronate Sodium Tablets, USP are available containing 5 mg, 30 mg, 35 mg or 150 mg risedronate sodium, USP.The 5 mg tablets are light beige, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4044-93bottles of 30 tabletsNDC 0378-4044-05bottles of 500 tabletsThe 30 mg tablets are white, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4114-93bottles of 30 tabletsNDC 0378-4114-05bottles of 500 tabletsThe 35 mg tablets are light orange, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4714-99unit of use blister card containing 4 tabletsNDC 0378-4714-92carton of 10 cards each containing 4 tabletsNDC 0378-4714-96unit of use blister card containing 12 tabletsNDC 0378-4714-78carton of 10 cards each containing 12 tabletsThe 150 mg tablets are light blue, film-coated, round, unscored tablets debossed with over on one side of the tablet and on the other side. They are available as follows:NDC 0378-4150-32unit of use blister card containing 1 tabletNDC 0378-4150-97carton of 10 cards each containing 1 tabletNDC 0378-4150-53unit of use blister card containing 3 tabletsNDC 0378-4150-93carton of 10 cards each containing 3 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Risedronate Sodium Tablets, USP are available containing 5 mg, 30 mg, 35 mg or 150 mg risedronate sodium, USP.The 5 mg tablets are light beige, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4044-93bottles of 30 tabletsNDC 0378-4044-05bottles of 500 tabletsThe 30 mg tablets are white, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4114-93bottles of 30 tabletsNDC 0378-4114-05bottles of 500 tabletsThe 35 mg tablets are light orange, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4714-99unit of use blister card containing 4 tabletsNDC 0378-4714-92carton of 10 cards each containing 4 tabletsNDC 0378-4714-96unit of use blister card containing 12 tabletsNDC 0378-4714-78carton of 10 cards each containing 12 tabletsThe 150 mg tablets are light blue, film-coated, round, unscored tablets debossed with over on one side of the tablet and on the other side. They are available as follows:NDC 0378-4150-32unit of use blister card containing 1 tabletNDC 0378-4150-97carton of 10 cards each containing 1 tabletNDC 0378-4150-53unit of use blister card containing 3 tabletsNDC 0378-4150-93carton of 10 cards each containing 3 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Risedronate Sodium Tablets, USP are available containing 5 mg, 30 mg, 35 mg or 150 mg risedronate sodium, USP.The 5 mg tablets are light beige, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4044-93bottles of 30 tabletsNDC 0378-4044-05bottles of 500 tabletsThe 30 mg tablets are white, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4114-93bottles of 30 tabletsNDC 0378-4114-05bottles of 500 tabletsThe 35 mg tablets are light orange, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4714-99unit of use blister card containing 4 tabletsNDC 0378-4714-92carton of 10 cards each containing 4 tabletsNDC 0378-4714-96unit of use blister card containing 12 tabletsNDC 0378-4714-78carton of 10 cards each containing 12 tabletsThe 150 mg tablets are light blue, film-coated, round, unscored tablets debossed with over on one side of the tablet and on the other side. They are available as follows:NDC 0378-4150-32unit of use blister card containing 1 tabletNDC 0378-4150-97carton of 10 cards each containing 1 tabletNDC 0378-4150-53unit of use blister card containing 3 tabletsNDC 0378-4150-93carton of 10 cards each containing 3 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Risedronate Sodium Tablets, USP are available containing 5 mg, 30 mg, 35 mg or 150 mg risedronate sodium, USP.The 5 mg tablets are light beige, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4044-93bottles of 30 tabletsNDC 0378-4044-05bottles of 500 tabletsThe 30 mg tablets are white, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4114-93bottles of 30 tabletsNDC 0378-4114-05bottles of 500 tabletsThe 35 mg tablets are light orange, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4714-99unit of use blister card containing 4 tabletsNDC 0378-4714-92carton of 10 cards each containing 4 tabletsNDC 0378-4714-96unit of use blister card containing 12 tabletsNDC 0378-4714-78carton of 10 cards each containing 12 tabletsThe 150 mg tablets are light blue, film-coated, round, unscored tablets debossed with over on one side of the tablet and on the other side. They are available as follows:NDC 0378-4150-32unit of use blister card containing 1 tabletNDC 0378-4150-97carton of 10 cards each containing 1 tabletNDC 0378-4150-53unit of use blister card containing 3 tabletsNDC 0378-4150-93carton of 10 cards each containing 3 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Risedronate Sodium Tablets, USP are available containing 5 mg, 30 mg, 35 mg or 150 mg risedronate sodium, USP.The 5 mg tablets are light beige, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4044-93bottles of 30 tabletsNDC 0378-4044-05bottles of 500 tabletsThe 30 mg tablets are white, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4114-93bottles of 30 tabletsNDC 0378-4114-05bottles of 500 tabletsThe 35 mg tablets are light orange, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4714-99unit of use blister card containing 4 tabletsNDC 0378-4714-92carton of 10 cards each containing 4 tabletsNDC 0378-4714-96unit of use blister card containing 12 tabletsNDC 0378-4714-78carton of 10 cards each containing 12 tabletsThe 150 mg tablets are light blue, film-coated, round, unscored tablets debossed with over on one side of the tablet and on the other side. They are available as follows:NDC 0378-4150-32unit of use blister card containing 1 tabletNDC 0378-4150-97carton of 10 cards each containing 1 tabletNDC 0378-4150-53unit of use blister card containing 3 tabletsNDC 0378-4150-93carton of 10 cards each containing 3 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Risedronate Sodium Tablets, USP are available containing 5 mg, 30 mg, 35 mg or 150 mg risedronate sodium, USP.The 5 mg tablets are light beige, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4044-93bottles of 30 tabletsNDC 0378-4044-05bottles of 500 tabletsThe 30 mg tablets are white, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4114-93bottles of 30 tabletsNDC 0378-4114-05bottles of 500 tabletsThe 35 mg tablets are light orange, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4714-99unit of use blister card containing 4 tabletsNDC 0378-4714-92carton of 10 cards each containing 4 tabletsNDC 0378-4714-96unit of use blister card containing 12 tabletsNDC 0378-4714-78carton of 10 cards each containing 12 tabletsThe 150 mg tablets are light blue, film-coated, round, unscored tablets debossed with over on one side of the tablet and on the other side. They are available as follows:NDC 0378-4150-32unit of use blister card containing 1 tabletNDC 0378-4150-97carton of 10 cards each containing 1 tabletNDC 0378-4150-53unit of use blister card containing 3 tabletsNDC 0378-4150-93carton of 10 cards each containing 3 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Risedronate Sodium Tablets, USP are available containing 5 mg, 30 mg, 35 mg or 150 mg risedronate sodium, USP.The 5 mg tablets are light beige, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4044-93bottles of 30 tabletsNDC 0378-4044-05bottles of 500 tabletsThe 30 mg tablets are white, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4114-93bottles of 30 tabletsNDC 0378-4114-05bottles of 500 tabletsThe 35 mg tablets are light orange, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4714-99unit of use blister card containing 4 tabletsNDC 0378-4714-92carton of 10 cards each containing 4 tabletsNDC 0378-4714-96unit of use blister card containing 12 tabletsNDC 0378-4714-78carton of 10 cards each containing 12 tabletsThe 150 mg tablets are light blue, film-coated, round, unscored tablets debossed with over on one side of the tablet and on the other side. They are available as follows:NDC 0378-4150-32unit of use blister card containing 1 tabletNDC 0378-4150-97carton of 10 cards each containing 1 tabletNDC 0378-4150-53unit of use blister card containing 3 tabletsNDC 0378-4150-93carton of 10 cards each containing 3 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Risedronate Sodium Tablets, USP are available containing 5 mg, 30 mg, 35 mg or 150 mg risedronate sodium, USP.The 5 mg tablets are light beige, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4044-93bottles of 30 tabletsNDC 0378-4044-05bottles of 500 tabletsThe 30 mg tablets are white, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4114-93bottles of 30 tabletsNDC 0378-4114-05bottles of 500 tabletsThe 35 mg tablets are light orange, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4714-99unit of use blister card containing 4 tabletsNDC 0378-4714-92carton of 10 cards each containing 4 tabletsNDC 0378-4714-96unit of use blister card containing 12 tabletsNDC 0378-4714-78carton of 10 cards each containing 12 tabletsThe 150 mg tablets are light blue, film-coated, round, unscored tablets debossed with over on one side of the tablet and on the other side. They are available as follows:NDC 0378-4150-32unit of use blister card containing 1 tabletNDC 0378-4150-97carton of 10 cards each containing 1 tabletNDC 0378-4150-53unit of use blister card containing 3 tabletsNDC 0378-4150-93carton of 10 cards each containing 3 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Risedronate Sodium Tablets, USP are available containing 5 mg, 30 mg, 35 mg or 150 mg risedronate sodium, USP.The 5 mg tablets are light beige, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4044-93bottles of 30 tabletsNDC 0378-4044-05bottles of 500 tabletsThe 30 mg tablets are white, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4114-93bottles of 30 tabletsNDC 0378-4114-05bottles of 500 tabletsThe 35 mg tablets are light orange, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4714-99unit of use blister card containing 4 tabletsNDC 0378-4714-92carton of 10 cards each containing 4 tabletsNDC 0378-4714-96unit of use blister card containing 12 tabletsNDC 0378-4714-78carton of 10 cards each containing 12 tabletsThe 150 mg tablets are light blue, film-coated, round, unscored tablets debossed with over on one side of the tablet and on the other side. They are available as follows:NDC 0378-4150-32unit of use blister card containing 1 tabletNDC 0378-4150-97carton of 10 cards each containing 1 tabletNDC 0378-4150-53unit of use blister card containing 3 tabletsNDC 0378-4150-93carton of 10 cards each containing 3 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:Risedronate Sodium Tablets, USP are available containing 5 mg, 30 mg, 35 mg or 150 mg risedronate sodium, USP.The 5 mg tablets are light beige, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4044-93bottles of 30 tabletsNDC 0378-4044-05bottles of 500 tabletsThe 30 mg tablets are white, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4114-93bottles of 30 tabletsNDC 0378-4114-05bottles of 500 tabletsThe 35 mg tablets are light orange, film-coated, round, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-4714-99unit of use blister card containing 4 tabletsNDC 0378-4714-92carton of 10 cards each containing 4 tabletsNDC 0378-4714-96unit of use blister card containing 12 tabletsNDC 0378-4714-78carton of 10 cards each containing 12 tabletsThe 150 mg tablets are light blue, film-coated, round, unscored tablets debossed with over on one side of the tablet and on the other side. They are available as follows:NDC 0378-4150-32unit of use blister card containing 1 tabletNDC 0378-4150-97carton of 10 cards each containing 1 tabletNDC 0378-4150-53unit of use blister card containing 3 tabletsNDC 0378-4150-93carton of 10 cards each containing 3 tabletsStore at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.PHARMACIST:


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and the endometrial changes that reduce the likelihood of implantation.

Non-Clinical Toxicology
Do not prescribe Lo-Zumandimine to women who are known to have the following:

Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke .

Prior administration of succinylcholine may enhance the neuromuscular blocking effect of vecuronium and its duration of action. If succinylcholine is used before vecuronium, the administration of vecuronium should be delayed until the succinylcholine effect shows signs of wearing off. With succinylcholine as the intubating agent, initial doses of 0.04 to 0.06 mg/kg of vecuronium may be administered to produce complete neuromuscular block with clinical duration of action of 25 to 30 minutes (see ).

The use of vecuronium before succinylcholine, in order to attenuate some of the side effects of succinylcholine, has not been sufficiently studied.

Other nondepolarizing neuromuscular blocking agents (pancuronium, d-tubocurarine, metocurine, and gallamine) act in the same fashion as does vecuronium; therefore, these drugs and vecuronium, may manifest an additive effect when used together. There are insufficient data to support concomitant use of vecuronium and other competitive muscle relaxants in the same patient.

Stop Lo-Zumandimine if an arterial or venous thrombotic (VTE) event occurs.

Based on presently available information on DRSP-containing COCs with 0.03 mg ethinyl estradiol (that is, Yasmin), DRSP-containing COCs may be associated with a higher risk of venous thromboembolism (VTE) than COCs containing the progestin levonorgestrel or some other progestins. Epidemiologic studies that compared the risk of VTE reported that the risk ranged from no increase to a three-fold increase. Before initiating use of Lo-Zumandimine in a new COC user or a woman who is switching from a contraceptive that does not contain DRSP, consider the risks and benefits of a DRSP-containing COC in light of her risk of a VTE. Known risk factors for VTE include smoking, obesity, and family history of VTE, in addition to other factors that contraindicate use of COCs .

A number of studies have compared the risk of VTE for users of Yasmin (which contains 0.03 mg of EE and 3 mg of DRSP) to the risk for users of other COCs, including COCs containing levonorgestrel. Those that were required or sponsored by regulatory agencies are summarized in Table 1. 

In addition to these “regulatory studies,” other studies of various designs have been conducted. Overall, there are two prospective cohort studies (see Table 1): the US post-approval safety study Ingenix [Seeger 2007], the European post-approval safety study EURAS (European Active Surveillance Study) [Dinger 2007]. An extension of the EURAS study, the Long-Term Active Surveillance Study (LASS), did not enroll additional subjects, but continued to assess VTE risk. There are three retrospective cohort studies: one study in the US funded by the FDA (see Table 1), and two from Denmark [Lidegaard 2009, Lidegaard 2011]. There are two case-control studies: the Dutch MEGA study analysis [van Hylckama Vlieg 2009] and the German case-control study [Dinger 2010]. There are two nested case-control studies that evaluated  the risk of non-fatal idiopathic VTE: the PharMetrics study [Jick 2011] and the GPRD study [Parkin 2011]. The results of all of these studies are presented in Figure 1. Although the absolute VTE rates are increased for users of hormonal contraceptives compared to non-users, the rates during pregnancy are even greater, especially during the post-partum period (see Figure 2). The risk of VTE in women using COCs has been estimated to be 3 to 9 per 10,000 woman-years. The risk of VTE is highest during the first year of use. Data from a large, prospective cohort safety study of various COCs suggest that this increased risk, as compared to that in non-COC users, is greatest during the first 6 months of COC use. Data from this safety study indicate that the greatest risk of VTE is present after initially starting a COC or restarting (following a 4 week or greater pill-free interval) the same or a different COC. The risk of thromboembolic disease due to oral contraceptives gradually disappears after COC use is discontinued. Figure 2 shows the risk of developing a VTE for women who are not pregnant and do not use oral contraceptives, for women who use oral contraceptives, for pregnant women, and for women in the postpartum period. To put the risk of developing a VTE into perspective: If 10,000 women who are not pregnant and do not use oral contraceptives are followed for one year, between 1 and 5 of these women will develop a VTE. If feasible, stop Lo-Zumandimine at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of thromboembolism. Start Lo-Zumandimine no earlier than 4 weeks after delivery, in women who are not breastfeeding. The risk of postpartum thromboembolism decreases after the third postpartum week, whereas the risk of ovulation increases after the third postpartum week. Use of COCs also increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events. COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes), although, in general, the risk is greatest among older (>35 years of age), hypertensive women who also smoke. COCs also increase the risk for stroke in women with other underlying risk factors. Oral contraceptives must be used with caution in women with cardiovascular disease risk factors. Stop Lo-Zumandimine if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal vein thrombosis immediately.

The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling:

Adverse reactions commonly reported by COC users are:

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).